Separate terms with OR to return results that match either term.
Clear All

700 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year (Ascending) FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J1932 Lanreotide (Cipla) Lanreotide Acetate 1mg Hormonal Therapy Somatostatin Analog No 2021 Sept. 27, 2022 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
BA Belzutifan Welireg 40mg Chemotherapy Miscellaneous Agent HIF-2 alpha Yes 2021 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sept. 27, 2022 In Use
J9298 Nivolumab & relatlimab-rmbw Opdualag 3mg/1mg Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 No 2022 Sept. 27, 2022 In Use

Found 700 results in 1 millisecondExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.